title: Thrombolysis in ischemic stroke: focus on new treatment strategies.
abstract: Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.
authors: IRCCS Centro Neurolesi Bonino- Pulejo, Messina, Italy. salbro77@tiscali.it
authors: Rocco S
authors: RS
authors: Calabro
authors: Giuseppe
authors: G
authors: Gervasi
authors: Placido
authors: P
authors: Bramanti
authors: Anna
authors: A
authors: Cavallini
mesh_terms: D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D015912:Thrombolytic Therapy
chemical_list: D005343:Fibrinolytic Agents